Two independent advances aim to address persistent manufacturing and potency bottlenecks in engineered‑cell therapeutics. A report described scalable processes for mass production of CAR‑iNK cells that promise to lower cost and increase batch throughput for NK‑based therapies. Separately, a survey of next‑generation engineered T cell innovations highlighted design improvements intended to broaden indications and improve safety. Both items underscore industry focus on manufacturing scale, off‑the‑shelf formats and engineering that improves therapeutic window.